Major Pharmas To Collaborate In Non-Profit Initiative To Resolve Clinical Development Hurdles
This article was originally published in PharmAsia News
Called TransCelerate BioPharma, the initiative funded by 10 big drug firms will work to develop uniform clinical data standards and certification for trial sites and investigators, with deliverables expected by mid-2013.
You may also be interested in...
Building on the Alzheimer’s disease Therapeutic Area Standard, the groups hope to create measurement standards for clinical trials in a variety of therapeutic areas, but funding remains an acute challenge. In order to succeed, each project needs to be faster and cheaper than the Alzheimer’s effort.
The onetime Celera CEO says his new attempt to centralize biological information into a massive database could lead to breakthroughs that extend the human life span. Behind that bold goal is a more mundane data-licensing strategy that, although not splashy, could still improve medicine.
Do high biotech share prices portend stock-heavy deal-making in lieu of all-cash transactions? Also, Biogen shares the risk with Eisai in an Alzheimer’s deal, while newly public Genocea and cell therapy specialist NeoStem both teamed with Harvard researchers.